Michael J Blaha1, Miguel Cainzos-Achirica2, Philip Greenland2, John W McEvoy2, Ron Blankstein2, Matthew J Budoff2, Zeina Dardari2, Christopher T Sibley2, Gregory L Burke2, Richard A Kronmal2, Moyses Szklo2, Roger S Blumenthal2, Khurram Nasir2. 1. From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins Medical Institutions, Baltimore, MD (M.J.B., M.C.-A., J.W.M., Z.D., R.S.B., K.N.); Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD (M.C.-A.); Departments of Medicine and Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (P.G.); Brigham and Women's Hospital, Boston, MA (R.B.); Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA (M.J.B.); Knight Cardiovascular Institute, Oregon Health and Science University, Portland (C.T.S.); Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (G.L.B.); University of Washington, Seattle (R.A.K.); Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (M.J.B., M.S.); Center for Healthcare Advancement and Outcomes, and Miami Cardiac and Vascular Institute, Baptist Heath South Florida, Miami (K.N.). mblaha1@jhmi.edu. 2. From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins Medical Institutions, Baltimore, MD (M.J.B., M.C.-A., J.W.M., Z.D., R.S.B., K.N.); Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, MD (M.C.-A.); Departments of Medicine and Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (P.G.); Brigham and Women's Hospital, Boston, MA (R.B.); Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA (M.J.B.); Knight Cardiovascular Institute, Oregon Health and Science University, Portland (C.T.S.); Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (G.L.B.); University of Washington, Seattle (R.A.K.); Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (M.J.B., M.S.); Center for Healthcare Advancement and Outcomes, and Miami Cardiac and Vascular Institute, Baptist Heath South Florida, Miami (K.N.).
Abstract
BACKGROUND: Limited attention has been paid to negative cardiovascular disease (CVD) risk markers despite their potential to improve medical decision making. We compared 13 negative risk markers using diagnostic likelihood ratios (DLRs), which model the change in risk for an individual after the result of an additional test. METHODS AND RESULTS: We examined 6814 participants from the Multi-Ethnic Study of Atherosclerosis. Coronary artery calcium score of 0, carotid intima-media thickness <25th percentile, absence of carotid plaque, brachial flow-mediated dilation >5% change, ankle-brachial index >0.9 and <1.3, high-sensitivity C-reactive protein <2 mg/L, homocysteine <10 µmol/L, N-terminal pro-brain natriuretic peptide <100 pg/mL, no microalbuminuria, no family history of coronary heart disease (any/premature), absence of metabolic syndrome, and healthy lifestyle were compared for all and hard coronary heart disease and all CVD events over the 10-year follow-up. Models were adjusted for traditional CVD risk factors. Among all negative risk markers, coronary artery calcium score of 0 was the strongest, with an adjusted mean DLR of 0.41 (SD, 0.12) for all coronary heart disease and 0.54 (SD, 0.12) for CVD, followed by carotid intima-media thickness <25th percentile (DLR, 0.65 [SD, 0.04] and 0.75 [SD, 0.04], respectively). High-sensitivity C-reactive protein <2 mg/L and normal ankle-brachial index had DLRs >0.80. Among clinical features, absence of any family history of coronary heart disease was the strongest (DLRs, 0.76 [SD, 0.07] and 0.81 [SD, 0.06], respectively). Net reclassification improvement analyses yielded similar findings, with coronary artery calcium score of 0 resulting in the largest, most accurate downward risk reclassification. CONCLUSIONS: Negative results of atherosclerosis-imaging tests, particularly coronary artery calcium score of 0, resulted in the greatest downward shift in estimated CVD risk. These results may help guide discussions on the identification of individuals less likely to receive net benefit from lifelong preventive pharmacotherapy.
BACKGROUND: Limited attention has been paid to negative cardiovascular disease (CVD) risk markers despite their potential to improve medical decision making. We compared 13 negative risk markers using diagnostic likelihood ratios (DLRs), which model the change in risk for an individual after the result of an additional test. METHODS AND RESULTS: We examined 6814 participants from the Multi-Ethnic Study of Atherosclerosis. Coronary artery calcium score of 0, carotid intima-media thickness <25th percentile, absence of carotid plaque, brachial flow-mediated dilation >5% change, ankle-brachial index >0.9 and <1.3, high-sensitivity C-reactive protein <2 mg/L, homocysteine <10 µmol/L, N-terminal pro-brain natriuretic peptide <100 pg/mL, no microalbuminuria, no family history of coronary heart disease (any/premature), absence of metabolic syndrome, and healthy lifestyle were compared for all and hard coronary heart disease and all CVD events over the 10-year follow-up. Models were adjusted for traditional CVD risk factors. Among all negative risk markers, coronary artery calcium score of 0 was the strongest, with an adjusted mean DLR of 0.41 (SD, 0.12) for all coronary heart disease and 0.54 (SD, 0.12) for CVD, followed by carotid intima-media thickness <25th percentile (DLR, 0.65 [SD, 0.04] and 0.75 [SD, 0.04], respectively). High-sensitivity C-reactive protein <2 mg/L and normal ankle-brachial index had DLRs >0.80. Among clinical features, absence of any family history of coronary heart disease was the strongest (DLRs, 0.76 [SD, 0.07] and 0.81 [SD, 0.06], respectively). Net reclassification improvement analyses yielded similar findings, with coronary artery calcium score of 0 resulting in the largest, most accurate downward risk reclassification. CONCLUSIONS: Negative results of atherosclerosis-imaging tests, particularly coronary artery calcium score of 0, resulted in the greatest downward shift in estimated CVD risk. These results may help guide discussions on the identification of individuals less likely to receive net benefit from lifelong preventive pharmacotherapy.
Authors: Omair Yousuf; Bibhu D Mohanty; Seth S Martin; Parag H Joshi; Michael J Blaha; Khurram Nasir; Roger S Blumenthal; Matthew J Budoff Journal: J Am Coll Cardiol Date: 2013-05-30 Impact factor: 24.094
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli Journal: Circulation Date: 2013-11-12 Impact factor: 29.690
Authors: Geoffrey H Tison; Chiadi E Ndumele; Gary Gerstenblith; Matthew A Allison; Joseph F Polak; Moyses Szklo Journal: Am J Cardiol Date: 2011-03-04 Impact factor: 2.778
Authors: Rajesh Tota-Maharaj; Michael J Blaha; John W McEvoy; Roger S Blumenthal; Evan D Muse; Matthew J Budoff; Leslee J Shaw; Daniel S Berman; Jamal S Rana; John Rumberger; Tracy Callister; Juan Rivera; Arthur Agatston; Khurram Nasir Journal: Eur Heart J Date: 2012-07-26 Impact factor: 29.983
Authors: Haitham M Ahmed; Michael J Blaha; Khurram Nasir; Steven R Jones; Juan J Rivera; Arthur Agatston; Ron Blankstein; Nathan D Wong; Susan Lakoski; Matthew J Budoff; Gregory L Burke; Christopher T Sibley; Pamela Ouyang; Roger S Blumenthal Journal: Am J Epidemiol Date: 2013-06-02 Impact factor: 4.897
Authors: Michael J Pencina; Ann Marie Navar-Boggan; Ralph B D'Agostino; Ken Williams; Benjamin Neely; Allan D Sniderman; Eric D Peterson Journal: N Engl J Med Date: 2014-03-19 Impact factor: 91.245
Authors: Ramzi Dudum; Omar Dzaye; Mohammadhassan Mirbolouk; Zeina A Dardari; Olusola A Orimoloye; Matthew J Budoff; Daniel S Berman; Alan Rozanski; Michael D Miedema; Khurram Nasir; John A Rumberger; Leslee Shaw; Seamus P Whelton; Garth Graham; Michael J Blaha Journal: J Cardiovasc Comput Tomogr Date: 2019-03-27
Authors: Leslee J Shaw; James K Min; Khurram Nasir; Joe X Xie; Daniel S Berman; Michael D Miedema; Seamus P Whelton; Zeina A Dardari; Alan Rozanski; John Rumberger; C Noel Bairey Merz; Mouaz H Al-Mallah; Matthew J Budoff; Michael J Blaha Journal: Eur Heart J Date: 2018-11-01 Impact factor: 29.983
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Mahmoud Al Rifai; Miguel Cainzos-Achirica; Sina Kianoush; Mohammadhassan Mirbolouk; Allison Peng; Josep Comin-Colet; Michael J Blaha Journal: Curr Treat Options Cardiovasc Med Date: 2018-09-26
Authors: Andreas D Knudsen; Andreas Fuchs; J Tobias Kühl; Ben A Arnold; Børge G Nordestgaard; Lars V Køber; Klaus F Kofoed Journal: Eur Radiol Date: 2018-05-03 Impact factor: 5.315